)
)
CNS Pharmaceuticals Investor Relations Material
Latest events
Investor Update
CNS Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from CNS Pharmaceuticals Inc
Access all reports
CNS Pharmaceuticals Inc. is a clinical-stage pharmaceutical company engaged in the development of anti-cancer drug candidates. Its primary focus is on treatments for primary and metastatic cancers of the brain and central nervous system malignancies. The company's flagship drug candidate, Berubicin, is a novel anthracycline, notable for being the first of its kind to cross the blood-brain barrier. This drug is currently in development for the treatment of glioblastoma multiforme (GBM), a particularly aggressive and currently incurable form of brain cancer. In addition to Berubicin, CNS Pharmaceuticals is advancing WP1244, a drug technology that leverages anthracycline and distamycin-based scaffolds to create potent small molecule agents. The company is headquartered in Houston, Texas, and its shares are listed on the Nasdaq.
Latest articles
)
Under the Hood: AutoZone's Blueprint for Retail Excellence
An in-depth look at the largest aftermarket auto parts retailer in the U.S., its philosophy, and masterful capital allocation.
19 Dec 2024
)
Lessons from Gautam Baid: Mastering Simplicity and Compounding
Gautam Baid's journey of compounding wisdom, investing simplicity, and lifelong learning – insights to transform your financial and personal growth.
13 Dec 2024
)
Rocket Lab: Breaking Ground in Space
Rocket Lab has been one of the pioneers in the commercial aerospace industry, with numerous satellite launches and space system applications.
9 Dec 2024
Ticker symbol
CNSP
Country
🇺🇸 United States